---
document_datetime: 2025-05-28 10:44:22
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/ibuprofen-genorph-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: ibuprofen-genorph-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.1241918
conversion_datetime: 2025-12-28 15:19:23.711254
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Ibuprofen Gen.Orph

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, please also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                         | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|-----------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IB /  | B.II.f.1.b Extension of the shelf life of the | 27/05/2025                          |                                             | SmPC                             |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000267682   | finished product - B.II.f.1.b.1 As packaged for sale (supported by real time data) - Accepted   |
|---------------------|-------------------------------------------------------------------------------------------------|